

Scd1 and monounsaturated lipids are required for autophagy and survival of adipocytes



Hiroiyuki Mori^{1,*}, Sydney K. Peterson¹, Rachel C. Simmermon¹, Katherine A. Overmyer^{2,3}, Akira Nishii¹, Emma Paulsson¹, Ziru Li¹, Annie Jen^{4,5}, Romina M. Uranga¹, Jessica N. Maung¹, Warren T. Yacawych¹, Kenneth T. Lewis¹, Rebecca L. Schill¹, Taryn Hetrick¹, Ryo Seino⁶, Ken Inoki¹, Joshua J. Coon^{2,3,4,5}, Ormond A. MacDougald^{1,7,**}

ABSTRACT

Objective: Exposure of adipocytes to ‘cool’ temperatures often found in the periphery of the body induces expression of Stearoyl-CoA Desaturase-1 (Scd1), an enzyme that converts saturated fatty acids to monounsaturated fatty acids. The goal of this study is to further investigate the roles of Scd in adipocytes.

Method: In this study, we employed Scd1 knockout cells and mouse models, along with pharmacological Scd1 inhibition to dissect the enzyme’s function in adipocyte physiology.

Results: Our study reveals that production of monounsaturated lipids by Scd1 is necessary for fusion of autophagosomes to lysosomes and that with a Scd1-deficiency, autophagosomes accumulate. In addition, Scd1-deficiency impairs lysosomal and autolysosomal acidification resulting in vacuole accumulation and eventual cell death. Blocking autophagosome formation or supplementation with monounsaturated fatty acids maintains vitality of Scd1-deficient adipocytes.

Conclusion: This study demonstrates the indispensable role of Scd1 in adipocyte survival, with its inhibition *in vivo* triggering autophagy-dependent cell death and its depletion *in vivo* leading to the loss of bone marrow adipocytes.

© 2024 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Keywords Scd1; Stearoyl CoA Desaturase 1; ADCD; Autophagy-dependent cell death; BMAT; Bone marrow adipose tissue; BMATs; Bone marrow adipocytes; MUFA; Monounsaturated fatty acid

1. INTRODUCTION

Temperatures at which cells function varies widely depending on location within the body. The core is typically maintained at around 37 °C whereas the shell — composed of peripheral extremities and subcutaneous regions of the trunk — displays a broader and generally cooler temperature range. Notably, adipocytes in subcutaneous, bone marrow, and dermal depots primarily exist at temperatures below 37 °C, contrasting with their visceral counterparts in the body’s core. In a previous study, we explored the adaptability of white adipocytes to temperature changes by subjecting them to 31 °C — the ‘cool’ temperature under which distal bone marrow and subcutaneous adipose tissues often exist when animals and humans are in a 22 °C environment [1,2]. This cool exposure induced expression of Stearoyl-CoA Desaturase-1 (Scd1), an enzyme that catalyzes conversion of saturated fatty acids to monounsaturated fatty acids [3].

Although Scd1 is expressed at low levels in most cell types, expression is much higher in lipogenic tissues including liver and white adipose tissue (WAT) [4]. Global Scd1 deletion in mice led to increased energy expenditure and insulin sensitivity [5]. Reduced Scd1 activity in liver and adipose tissues was not sufficient to elicit the phenotypes of global *Scd1*KO mice (GKO) [6–8]. Interestingly, skin-specific *Scd1* knockout mice had increased water and heat loss across the skin surface, and thus recapitulated the hypermetabolic phenotype observed in global *Scd1*KO mice [9]. We previously reported that Scd1 expression is regulated by temperature, with considerably more Scd1 protein observed in bone marrow and subcutaneous adipose tissues of rodents housed at 22 °C compared to 29 °C [3]. Consistent with elevated Scd1, decreased amounts of saturated lipids and increased proportions of monounsaturated lipids were observed within triacylglycerols of bone marrow adipose tissue (BMAT) and gluteal WAT of rodents housed at 22 °C [3].

¹Department of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, USA ²Morgridge Institute for Research, Madison, WI, USA ³National Center for Quantitative Biology of Complex Systems, Madison, WI, USA ⁴Department of Biomolecular Chemistry, University of Wisconsin, Madison, WI, USA ⁵Department of Chemistry, University of Wisconsin, Madison, WI, USA ⁶Dojindo Molecular Technologies, Inc., Rockville, MD, USA ⁷Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA

*Corresponding author. E-mail: morimori@umich.edu (H. Mori).

**Corresponding author. Department of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, USA. E-mail: macdouga@umich.edu (O.A. MacDougald).

Received November 25, 2023 • Revision received February 29, 2024 • Accepted March 11, 2024 • Available online 14 March 2024

<https://doi.org/10.1016/j.molmet.2024.101916>

Scd1 and monounsaturated fatty acids (MUFAs) are associated with several functions in adipose and other tissues. In addition to lipid and carbohydrate metabolism, Scd1 also plays roles in production of adipokines, insulin sensitivity, endoplasmic reticulum stress, cancer cell survival, and autophagy [10–12]. Autophagy consists of forming double-membrane vesicles encapsulating protein aggregates, damaged organelles such as mitochondria, and bulk cytoplasm, which then fuse with lysosomes to degrade and recycle their contents [13–15]. Although it is traditionally viewed as an adaptive process enabling cells to survive stresses like nutrient deprivation, increasing evidence suggests autophagy may mediate cell death during development and pathogenesis [13,14,16]. However, significant gaps remain in our understanding of autophagy-dependent cell death (ADCD) [13]. The interplay between *de novo* lipogenesis and autophagy has emerged as a fascinating area of study in cellular biology. Fatty acids produced by fatty acid synthase (Fasn) are essential for the autophagy process including autophagosome and lysosome maturation and fusion in adipocytes [17]. The relationships between lipogenesis and autophagy are fundamental cell biological processes in that acetyl-CoA carboxylase1 (Acc1), the rate-limiting step of fatty acid biosynthesis, promotes autophagy and survival in chronologically aging yeast [18]. In addition, deficiency of the *Scd1* orthologue in yeast demonstrated that MUFAs are required for formation of autophagosomes [10]. However, to what extent *de novo* lipogenesis and Scd1 contribute to the control of autophagy in adipocytes remains elusive.

To further investigate roles of Scd1 in adipocytes, particularly in relation to cool temperature adaptation, we employed a genetic approach using Scd1 knockout cells and mice, along with pharmacological inhibition of Scd1. Our observations did not suggest that Scd1-deficiency leads to beige adipocyte formation, as previously suggested [19], but instead pointed to Scd1 inhibition causing adipocyte death. Our exploration of cell death processes in Scd1-deficient adipocytes revealed that both pharmacological and genetic inhibition of Scd1 in adipocytes causes ADCD. Impaired fusion of autophagosomes to lysosomes, coupled with reduced lysosomal acidification in *Scd1*KO adipocytes, resulted in vacuole accumulation and ultimately, cell death. Our argument is substantiated by evidence that blocking autophagosome formation protects *Scd1*KO adipocytes from cell death, a result analogous to the cell survival observed after supplementation of Scd1-deficient adipocytes with MUFAs.

2. RESULTS

2.1. Beige adipocyte markers were not induced in *Scd1*KO adipocytes

Scd1 resides in the endoplasmic reticulum where it converts Coenzyme A-derivatives of palmitic (C16:0) and stearic (C18:0) acids to palmitoleic (C16:1, n-7) and oleic (C18:1, n-9) acids, respectively. We recently reported that exposure of cultured adipocytes to cool temperatures (31 °C) increases expression of Scd1 (Figure 1A) [3]. To determine whether increased monounsaturated fatty acids (MUFAs) under cool stimulation was dependent on Scd1, we performed lipidomic analyses of *Scd1* KO adipocytes (Figures 1B and S1). Cool adaptation of control adipocytes increased the proportion of several MUFA-containing lipid species, including triacylglycerol (TAG), phosphatidylcholine (PC), phosphatidylinositol (PI), and phosphatidylethanolamine (PE), and these lipids were reduced in *Scd1*KO adipocytes at both 37 °C and 31 °C (Figures 1A, B, and S1). In contrast, lipid species containing mainly saturated lipids were often suppressed with cool adaptation and were more abundant in *Scd1*KO adipocytes (Figures 1B,

and S1). These data suggest that induction of Scd1 with cool adaptation increases lipid monounsaturations, and that Scd1 is the predominant SCD isoform in cultured adipocytes.

It was reported that cultured Scd1 knockout cells are prone to being and have impaired lipid accumulation during adipogenesis [19]. Consistent with this observation, we observed that some *Scd1*KO mesenchymal stem cells (MSC) adipocytes and Cre-infected *Scd1^{fl/fl}* adipocytes acquire a brown morphology characterized by an aggregation of compact brown structures during terminal differentiation (Figures 1C, F, and S2A). We performed immunoblot analyses to confirm that this morphology is related to beige adipogenesis and observed no Ucp1 induction in *Scd1*KO adipocytes (Figure 1D and G). Furthermore, beige adipocyte markers, including *Ppargc1a*, *Fgf21*, *Cox8b* and *Prdm16* [20–24] were not consistently induced in *Scd1*KO adipocytes (Figure 1E and H). Taken together, these data indicate that although Scd1 deficiency caused aggregations of brown structures reminiscent of beige adipocytes, these cells did not acquire molecular characteristics of beige under our experimental conditions.

2.2. Brown structures in *Scd1*KO MSC adipocytes are features of cell death

We next investigated whether brown structures newly arose or were transformed from existing cells. Time-lapse microscopy revealed that brown aggregates formed on lipid droplets of differentiating adipocytes (Figure 2A). This morphological change occurred rapidly, and brown structures formed within a 2-hour duration of imaging. To evaluate whether adipocytes containing brown structures were viable or dead, we first observed that they were efficiently labeled with Trypan blue (Figure 2B), suggesting that they were dead. To confirm cell death by another method, Calcein-AM and ethidium homodimer (EthD-1) dyes were used. Whereas almost all control adipocytes were stained with Calcein-AM as a live cell marker, fewer cells were Calcein-AM positive in *Scd1*KO adipocytes (Figure 2C). Increased frequency of EthD-1 positive nuclei, an indicator of dead and dying cells, was observed in *Scd1*KO adipocytes. EthD-1 positive nuclei were also frequently observed in *Scd1*KO adipocytes not stained with Calcein-AM and containing brown structures (Figure 2C).

Next, to examine whether pharmacological inhibition of Scd1 induced cell death in cultured adipocytes, MSCs were differentiated for 6 days, then treated with SCD inhibitors for 4 days. All three Scd1 inhibitors (CAY10566, A-939572, and MF-438) at a concentration of ~30 nM induced brown structures (Figure S2B) that appeared similar to morphological changes observed adipocytes genetically deficient for Scd1. This phenomenon was also evident in adipocytes derived from human SVCs treated with an Scd1 inhibitor (Figure S2C). Consistent with the *Scd1*KO adipocytes, brown structure formation induced by Scd1 inhibitors also displayed EthD-1 positive nuclei (Figure 2D), suggesting pharmacological inhibition of Scd1 also induces cell death in cultured adipocytes. Taken together, these results indicate that pharmacological inhibition and genetic deficiency of Scd1 cause adipocyte death *in vitro*. Of note, staining patterns illustrate cell death stages in *Scd1*KO adipocytes: The brown structures predominantly stain positive for EthD-1, confirming cell death (Figure S2D). A proportion of the structures exhibit only Hoechst positivity, which may indicate cells at an earlier stage of death or with compromised membrane integrity but not complete cell lysis (Figure S2D; left segment of the bar graph). Some brown structures are not stained with either EthD-1 or Hoechst, suggesting complete cell lysis and loss of nuclear material (Figure S2D; right segment of




Figure 1: Beige adipocyte markers are not induced in *Scd1*KO adipocytes. (A) *Scd1* converts saturated fatty acids (e.g., palmitic and stearic acids) to monounsaturated fatty acids (e.g., palmitoleic and oleic acids, respectively). *Scd1* is induced at 31 °C and is undetectable in *Scd1*-KO adipocytes. MSCs from control and global *Scd1* KO mice were cultured at 37 °C prior to and for the first four days of adipogenesis, after which cells were moved to 31 °C for 12 days. (B) Decreased monounsaturated lipids (upper panels) and increased saturated lipids (lower panels) in *Scd1*KO adipocytes. Adipocytes were cultured at 37 °C or 31 °C for 12 days. Peak area of each lipid is expressed as fold change relative to 37 °C control ($n = 3$). Data are presented as mean \pm SD. * $p < 0.05$. (C) Cultured *Scd1*KO adipocytes acquire brown morphological structures during terminal differentiation. Scale bar indicates 100 μm . (D) Undetectable *Ucp1* expression in *Scd1*KO adipocytes for the indicated days after differentiation. Eleven μg of MSC-derived adipocyte (AD-MSC) or 0.1 or 0.5 μg BAT lysate was evaluated by immunoblot for *Ucp1*. Data is representative of 3 independent experiments. (E) Beige adipocyte markers were not induced in *Scd1*KO adipocytes except *Prdm16* at Day 8 ($n = 4$). Gene expression was normalized to geometric mean value of *Hprt*, *Gapdh*, *Ppia*, and was expressed relative to control at Day 4 ($n = 4$). * $p < 0.05$. Data is representative of 2 independent experiments. (F–H) Differentiated adipocytes from *Scd1*^{fl/fl} stromal vascular cells (SVCs) were treated with adenoviral GFP or adenoviral Cre recombinase at Day 4 of differentiation. (F) Morphology of *Scd1*KO adipocytes is characterized by aggregations of brown structures. Scale bar indicates 50 μm . (G) *Scd1* and *Ucp1* protein expression in adipocytes following adenoviral GFP or Cre infection. Eleven μg of adipocyte or 0.1 or 0.5 μg BAT lysate was evaluated by immunoblot for *Ucp1*. (H) Beige adipocyte markers were not induced in *Scd1*KO adipocytes except *Fgf21* ($n = 4$). Gene expression was normalized to geometric mean value of *Hprt*, *Gapdh*, *Ppia*, *Rpl32*, and was expressed relative to non-infected adipocytes ($n = 4$). * $p < 0.05$.

the bar graph). Additionally, nuclei stained with both EthD-1 and Hoechst were detected in the media following centrifugation of stained *Scd1*KO adipocyte cultures (Figure S2D; bottom panel), suggesting a cell death mechanism that in some cases involves nuclear extrusion.

2.3. MUFA supplementation rescues adipocytes from cell death induced by *Scd1* deficiency

Pharmacological and genetic inhibition of *Scd1* causing adipocyte death led us to investigate next whether MUFAs, the enzymatic products of *Scd1*, protect adipocytes against the formation of brown




Figure 2: Brown structures in *Scd1*KO MSC adipocytes are features of cell death. (A) Representative pictures of time-lapse recording for *Scd1*KO MSC adipocytes acquiring brown structures. Cultured *Scd1*KO adipocytes were monitored every 2 h from Day 4 (0 h) to Day 7 (70 h). Difficulty with maintenance of focus during data acquisition resulted in some lipid droplets appearing to have double membranes. (B) *Scd1*KO adipocytes with brown structures are dead, and stain positive with trypan blue. Adipocytes were stained with Trypan blue at Day 8 after differentiation. (C) Staining with cell death indicator, EthD-1, was observed in *Scd1*KO adipocytes. Adipocytes cultured in DMEM/F12 with 2% FBS were stained with a live cell marker Calcein AM, dead cell marker EthD-1, and Hoechst at Day 8 after differentiation. (D) Adipocyte death caused by pharmacological inhibition of *Scd1*. Adipocytes were cultured with SCD inhibitors: 30 nM CAY10566 or 30 nM A-939572 for 4 days, then stained EthD-1, and Hoechst. Data shown in (B)–(D) are representative of at least 3 independent experiments.

structures and cell death. In *Scd1*KO adipocytes, supplementation with 100 μ M palmitoleic (C16:1) or oleic (C18:1) acids, or a mixture of both MUFAs (50 μ M each) from day 4–8 of differentiation blocked the death of adipocytes (Figure 3A–C). Whilst addition of palmitic acid (C16:0) to *Scd1*KO adipocytes did not rescue these phenotypes, it caused formation of additional brown structures compared to BSA-treated cells (Figure 3A–C). Brown-colored structures were less stained with BODIPY or Oil Red O than normal lipid droplets (Figures 3B and S2A). There were no identified toxic signs attributed to this concentration of non-esterified fatty acids in control adipocytes. To determine whether MUFAs also rescue cell death induced by *Scd1* inhibitors, adipocytes were cultured with *Scd1* inhibitors with or without a 1:1 mixture of 50 μ M palmitoleic and oleic acids. The number of dead adipocytes

induced by pharmacological inhibition of *Scd1* was decreased with MUFA supplementation (Figure 3D). Taken together, these data suggest that conversion of saturated lipids to monounsaturated lipids is critical to protect adipocytes deficient for *Scd1* from cell death.

2.4. Decreased bone marrow adipose tissue (BMAT) volume and number in proximal and distal tibiae in bone marrow adipocyte (BMA) specific *Scd1* knockout mouse

To determine whether *Scd1* is required for survival of adipocytes *in vivo*, we knocked *Scd1* out of BMA, a cell type that expresses high levels of *Scd1* when mice are housed at 22 $^{\circ}$ C [3]. BMA-specific *Scd1* knockout (BMA-*Scd1*KO) mice were generated by crossing *Scd1*^{fl/fl} mice with a BMA-*Cre* mouse model [25]. First, we validated deletion




Figure 3: Supplementation of *Scd1*KO adipocytes with MUFAs maintains cell viability. (A–C) Supplementation with 100 μ M palmitoleic (C16:1) or 100 μ M oleic (C18:1) acids, or a mixture of 50 μ M of each MUFA to *Scd1*KO adipocytes from day 4–8 of differentiation reduced appearance of brown structures. Addition of palmitic acid (C16:0) increased frequency of brown structures in *Scd1*KO adipocytes. (A) Phase contrast microscopy. (B) Fluorescent microscopy of cells following staining of neutral lipid droplets with BODIPY. (C) Quantification of brown structures observed per field. Brown structures were quantified from 10 fields in each group as shown in (A), with each field measuring 0.561 mm². **p* < 0.05. Data shown are representative of at least 3 independent experiments. (D) Supplementation with a MUFA mixture blocked adipocyte death following *Scd1* inhibition. Adipocytes were cultured with SCD inhibitors – 30 nM CAY10566 or 30 nM A-939572 for 4 days with or without a mixture of MUFAs (50 μ M of palmitoleic and oleic acids). Controls were treated with BSA alone. Brown structures were quantified from 9 fields in each group, with each field measuring 0.561 mm². **p* < 0.05.

of *Scd1* in caudal vertebrae, where constitutive bone marrow adipocytes (cBMAd) comprise ~4% of total cellularity, and observed reduced expression of *Scd1* in BMAd-*Scd1*KO mice (Figure 4A). Based on the lack of *Ucp1* expression in *Scd1*KO BMAT (Figure S3A), the deletion of *Scd1* did not induce beigeing. No reduction in *Scd1* was observed in WAT depots, where adipocytes are more plentiful (~20%) than in caudal vertebra. Differentiated MSCs from control and *Scd1* KO mice were included as immunoblot controls (Figure 4A). To confirm the

functional impact of *Scd1* deletion in BMAT, we performed lipidomic analyses on distal tibia and caudal vertebra, both of which have significant amounts of BMAT. We focused our analyses on TAG and diacylglycerols (DAG) that are abundant in BMAds, rather than phospholipids, which are found in all cells and thus dilute specific effects of *Scd1* deficiency in BMAds. We confirmed the expected enzymatic roles of *Scd1* in BMAds, and generally observed lipids with decreased monounsaturated lipids and increased saturated lipids in BM-*Scd1*KO




Figure 4: Decreased BMAT in proximal and distal tibiae of *BMAd-Scd1* KO mice. Control and *BMAd-Scd1* KO mice of both sexes were analyzed at 24–26 weeks of age, including 11 male control, 14 male KO, 10 female control, and 13 female KO mice. (A) Expression of Scd1 in tail of *Scd1*KO BMAT is reduced but not in sWAT and gWAT depots. Lysates from cultured adipocytes derived from control and *Scd1*KO mice were used as controls. Control and *BMAd-Scd1*KO mice of both sexes were analyzed at 24–26 weeks of age, including 11 male control, 15 male KO, 10 female control, and 14 female KO mice. (B–D) Decalcified tibiae were treated with osmium tetroxide and quantified by μ CT analyses to measure the BMAT volume at proximal and distal ends of the tibia. Data are presented as mean \pm SD * p < 0.05. (E and F) Representative images of male proximal tibial BMAT (E) and distal tibial BMAT (F). Scale bar, 200 μm . (G and H) Quantitative analyses of BMAd sizes were performed with MetaMorph software. Data are presented as mean \pm SD * p < 0.05.

tibia and caudal vertebrae (CV) (Figure S3B). No genotype-specific differences were observed in *BMAd-Scd1*KO mice, including body weight, length, lean or fat mass, weights of WATs, and glucose tolerance (Figure S4A–F). A slight increase in insulin sensitivity was observed in male *BMAd-Scd1*KO mice (Figure S4G), whereas there was no change in insulin sensitivity in female mice (Figure S4H). To quantify effects of Scd1-deficiency on bone marrow adiposity and cellularity, we used osmium tetroxide and μ CT of tibia, and hematoxylin and eosin staining of BMAT sections. Regulated BMAT (rBMAT) volume was decreased in the proximal tibia of both sexes and constitutive BMAT (cBMAT) volume was reduced in distal tibia of male *BMAd-Scd1*KO mice (Figure 4B–D). Histological analyses revealed decreased rBMAd number in proximal tibiae of *BMAd-Scd1*KO mice (Figures 4E, S5A, and S5B). Depletion of Scd1 caused smaller size of cBMAd in distal tibia only in male mice (Figures 4F–H, S5C–E). Although loss of BMAds has been shown to cause elevated bone mass [26], no differences were observed in bone volume fraction, bone mineral density, or other measure of bone mass in male and female *BMAd-Scd1*KO mice compared to controls (Figure S5F–K). The size of adipocytes in WAT was not affected in *BMAd-Scd1*KO mice (Figure S5L–M).

2.5. *Scd1*KO adipocytes do not die via canonical apoptotic or necroptotic pathways but undergo autophagy-dependent cell death (ADCD)

While death of cancer cells has been linked to inhibition of Scd1 activity [27], mechanisms associated with cell death induced by Scd1 inhibition vary, including apoptosis, ferroptosis, and autophagy [27]. One potential explanation for this diversity may stem from varying levels of

Scd1 expression in cancer cell models (Figure S6) and differing extent of Scd1 inhibition [28–32]. We next investigated which type of cell death occurs in the adipocytes deficient for Scd1. Apoptotic signaling activates a caspase cascade; the initiator caspases in turn cleave and activate downstream effector caspases. However, there was no induction of cleaved caspase 3 in either control or *Scd1*KO adipocytes, whereas adipocytes treated with apoptosis inducers such as thapsigargin or tunicamycin showed robust cleavage of caspase 3 (Figure S7A). Necroptosis is a programmed form of necrosis that involves phosphorylation of MLKL. Whereas neither control nor *Scd1*KO adipocyte samples showed evident MLKL phosphorylation, induction of necroptosis was observed in these adipocytes treated with the necroptosis inducers (TSZ: TNF- α , SM-164, and VAD-fmk) (Figure S7B). Consistent with these findings, neither the apoptotic inhibitor ZVAD nor three necroptotic inhibitors (i.e. necrostatin, GSK 872, and necrosulfonamide) prevented *Scd1*-deficiency from causing death of adipocytes, unlike the successful intervention achieved by 16:1 supplementation (Figure S7C). Although Scd1 inhibition has been reported to trigger ferroptosis and death of ovarian cancer cells [27,32], inhibitors of ferroptosis (i.e. ferrostatin, liproxstatin 1, or SRS 11-92) were not sufficient to rescue death of *Scd1*KO adipocytes, as compared to supplementation with MUFAs (Figure S7C and D). To confirm the absence of apoptosis characteristics, such as nuclear condensation or apoptotic body formation, and necrosis characteristics, such as cell swelling, we evaluated adipocyte morphology with transmission electron microscopy (TEM). We did not observe the typical indications of apoptosis, such as chromatin condensation and fragmentation, or the main features of necrosis, such as cell swelling (Figure 5A). Importantly, unlike control adipocytes, which display




Figure 5: *Scd1*KO adipocytes undergo ADCD rather than by canonical apoptotic or necroptotic pathways. (A) MSC adipocytes were fixed on day 8 after differentiation for examination by transmission electron microscopy (TEM). Scale bar; 2 μ m. (B) Schematic diagram of different steps of autophagy. (C) To prevent autophagy induced by nutrient deprivation, adipocytes from MSCs at indicated times after differentiation were changed with fresh media one day before assay, then with fresh DMEM/F12 (7.8 mM glucose) with 2% FBS for 4 h before harvesting with or without 100 nM of bafilomycin A for 2 h. Autophagy-related proteins in control and *Scd1*KO adipocytes were examined by immunoblotting using indicated primary antibodies. (D) Immunocytochemistry to detect lysosome-associated membrane protein-2 (Lamp2; red), p62 as an autophagic marker (deep red), perilipin (lipid droplet; green), or Hoechst 33342 (nuclei; blue) on MSC adipocytes after treatment with 100 nM bafilomycin A and 10 nM rapamycin A for 3 h. Scale bar indicates 50 μ m. (E–G) Autophagy is required for *Scd1* inhibition to cause adipocyte death. MSCs from *Atg7^{fl/fl}* mice were induced to differentiate and at day 4, adipocytes were infected with adenoviral vectors carrying *Gfp* (control) or *Cre* (*Atg7*KO) genes. (E) Immunoblot analysis of *Atg7* expression and controls for autophagy (beclin), loading (laminin) and adipogenesis (Fabp4). (F) Following adenoviral infection, adipocytes were cultured with 30 nM of CAY10566 from Day 6 to Day 10. Treatment with 50 μ M each of palmitoleic (C16:1) and oleic (C18:1) acids was used as the standard for rescue of cell viability. Scale bar indicates 50 μ m. (G) The average number of brown structures per field (0.561 mm²) was quantified after photomicroscopy of 6 fields per group. **p* < 0.05. Data shown in (C)–(F) are representative of at least 3 independent experiments.

uniformly electron-dense lipid droplets, *Scd1*KO adipocytes contain many vacuoles with differing electron densities (Figure 5A), and likely correspond to brown structures observed with light microscopy (Figures 2B and 3A).

Large numbers of small vacuoles present in the cytoplasm is a characteristic feature of ADCD [13]. It has been proposed that three criteria must be met to determine whether cells die by ADCD. These are to 1) exclude other forms of cell death, 2) observe an increase in autophagic flux, and 3) determine whether blockade of autophagy rescues cell viability [13,16]. We did not find evidence for death by apoptosis, necroptosis, or ferroptosis (Figure S7); thus, we evaluated autophagic flux by accumulation of lipidated LC3B (LC3B-II) and p62

(Figure 5B) and found no obvious change in basal rate of autophagy between control and *Scd1*KO adipocytes (Figure 5C). In addition, inhibition of lysosomal v-ATPase activity with bafilomycin A1 increased LC3-II and p62 similarly between genotypes (Figure 5C). Interestingly, lysosomal markers including Lamp1 and Lamp2 were increased in *Scd1*KO adipocytes and with bafilomycin A1 treatment. We speculated that immunoblot using whole cell lysates might not detect increased autophagic flux in our model since *Scd1*KO adipocytes did not undergo synchronized cell death (Figure 2A). Consistent with this idea, immunocytochemical analyses of p62, which is recruited to autophagosomes forming punctate structures [33], revealed that *Scd1*KO adipocytes had increased p62 puncta at baseline, and following




Figure 6: Impaired lysosomal acidification in *Scd1*KO adipocytes is necessary for death of *Scd1*KO adipocytes. (A and B) Lysosome isolation and enrichment for Day 6 control and *Scd1*KO adipocytes was achieved by cell disruption followed by differential centrifugation and density gradient fractionation. (A) Whole cell lysate (WCL) and lysosomal lysate from control or *Scd1*KO adipocytes were examined by immunoblotting using primary antibodies to lysosome markers: Lamp1/2, Atp6v0a1, Abhd6: Alpha/Beta-Hydrolase Domain-Containing 6, and Limp2: Lysosomal integral membrane protein 2 (B) Gene Set Enrichment Analysis (GSEA) of lysosomal proteomics data ($n = 4$) was conducted using the Gene Ontology gene set, with plots separated into GO Biological Process (GOBP). The visualizations display the top 10 upregulated and top 10 downregulated pathways, all of which have FDR-adjusted p -values < 0.05 . (C–D) Reduced numbers of intact lysosomes in *Scd1*KO adipocytes. MSC adipocytes were stained with LysoPrime Green for specific localization of lysosomes, and pHLys Red as a measure of lysosomal pH. Scale bar indicates 20 μm (C). Numbers of adipocytes with non-acidic lysosomes per field (0.045 mm^2) were estimated from eight independent fields per group (D). (E–F) Decreased autolysosomes in *Scd1*KO adipocytes. Cultured adipocytes were stained with DAPRed for autophagosome detection, and DALGreen as a measure of vesicle acidity. Scale bar indicates 20 μm (E). Adipocytes with non-acidic autophagosomes per field (0.045 mm^2) were quantified in eight independent fields per group (F). (G–H) Lysosomal acidification in *Scd1*KO adipocytes is necessary for *Scd1*KO cell death. Control and *Scd1*KO MSC adipocytes were treated with 30 nM bafilomycin A1 from Day 4 after differentiation for 24 h. Photos were taken at Day 6. Scale bar indicates 50 μm . (G). Brown structures per field (0.561 mm^2) were quantified in 10 different fields/in each group (H). * $p < 0.05$.

bafilomycin A1 and rapamycin treatment (Figures 5D and S8A). Finally, to evaluate whether blockage of autophagy caused cell death upon *Scd1* deletion, we generated *Atg7* knockout adipocytes by infecting adenoviral Cre recombinase into *Atg7^{fl/fl}* MSC adipocytes (Figure 5E). Whereas cell death significantly increased upon *Scd1* inhibition with CAY10566 (30 nM for 4 days) in control GFP-infected adipocytes, *Atg7*KO adipocytes did not form brown structures and undergo cell death with the same treatment (Figure 5F and G). Taken together, these data indicate that inhibition of *Scd1* in adipocytes leads to ADCC *in vitro*. Of note, although TEM analyses showed more vacuole formation in *Scd1*KO BMADs compared to control BMADs (Figure S7E), we were unable to confirm whether these are equivalent to vacuoles observed in *Scd1*KO adipocytes *in vitro*.

2.6. Impaired lysosomal acidification is necessary for death of *Scd1*KO adipocytes

Increased expression of lysosomal proteins in *Scd1*KO adipocytes (Figure 5C) led us to investigate further the potential relationships between lysosomal function and *Scd1*KO cell death. Lysosome isolation and enrichment from both control and *Scd1*KO adipocytes were achieved by differential centrifugation and density gradient fractionation. Exclusion of basement membrane after separation is shown by the absence of laminin (Figure 6A). Surprisingly, immunoblot analyses revealed reduced expression of Lamp1 and Lamp2 proteins in *Scd1*KO lysosomes whereas their abundance in whole-cell lysate was elevated (Figure 6A). Expression of V-ATPase (ATP6V0A1), which pumps protons into the lysosome, is also decreased in *Scd1*KO lysosomes relative

to expression of a late endosomal/lysosomal protein, ABHD6 (Figure 6A). To identify and quantify abundance of purified proteins, we performed proteomics of lysosomal enrichments from both genotypes. Gene Set Enrichment Analysis (GSEA) of lysosomal proteomics data was conducted using the Gene Ontology gene set with plots separated into GO Biological Process (GOBP). Upregulated pathways in the *Scd1*KO lysosomes were related to mitochondria (Figure 6B), perhaps indicative of dysregulated fusion of mitophagic vacuoles with lysosomes, or increased tethering of lysosomes with mitochondria [34]. In contrast, GOBP predicts downregulated pathways related to lysosome including Protein Localization to Lysosome, and Lytic Vacuole Transport (Figure 6B).

As noted above, we observed decreased recovery of proteins that regulate lysosomal pH including Lamp1/2 and Atp6v0a1(V-ATPase) (Figure 6A) [35]; thus, we hypothesized that lysosomes in *Scd1*KO adipocytes have impaired acidification. To test this hypothesis, MSC adipocytes were stained with LysoPrime Green, a lysosome probe resistant to pH change, for localization of lysosomes, and pHlysRed, a specific probe for acidic lysosome, to indicate extent of lysosomal acidity. Whereas acidic punctate lysosomal structures were readily observed in control adipocytes as indicated by yellow dots in the merged picture (Figure 6C top and D), a subset of *Scd1*KO adipocytes were unable to acidify lysosomal vacuoles, and thus were green due to staining by LysoPrime but not by pHlysRed (Figure 6C bottom and D). We next investigated autolysosome formation with DAPRed for detecting autophagosomes, and vacuole acidity with DALGreen, whose fluorescent becomes stronger as acidity increases. In control adipocytes, autolysosomes were observed as yellow dots in the merged picture, suggesting that autophagosomes were efficiently fused with lysosomes (Figure 6E and F). On the other hand, two distinct staining patterns were observed in *Scd1*KO adipocytes. Firstly, there were adipocytes with numerous red autophagosome puncta that were not acidic (Figure 6E and F), suggesting that *Scd1* deficiency might cause impaired fusion between autophagosomes and lysosomes, or that autophagosomes might have fused successfully with non-acidic lysosomes. Secondly, there were adipocytes with a elevated numbers of acidified autolysosomes, as indicated by the yellow color in the merged picture (Figure 6E and F). Aside from the fact that *Scd1*KO adipocytes did not undergo synchronized cell death (Figure 2A), the steady state degree of autophagic compensation and decompensation within *Scd1*KO adipocytes did not result in elevated autophagy flux, as detected by immunoblotting. However, prior to death, *Scd1*KO adipocytes have an excess of autophagosomes, which may result from an imbalance between autophagy initiation and lysosomal degradation.

To evaluate importance of lysosomal acidification on the viability of *Scd1*KO adipocytes, control and *Scd1*KO adipocytes were treated with bafilomycin A1, from Day four of differentiation for 24 h. At day six of adipogenesis, inhibition of v-ATPase significantly increased cell death in *Scd1*KO adipocytes but had little effect in control adipocytes. These observations indicate that further impairment of lysosomal acidification increases susceptibility to cell death in *Scd1*KO adipocytes (Figure 6G and H). Taken together, these data indicate that *Scd1* is required to maintain lysosomal acidity, and that impairment of this process results in accumulation of autophagosomes and death of *Scd1*KO adipocytes.

3. DISCUSSION

3.1. Comparison of *Scd1* knockout phenotypes between our study and others

The genetic basis for a spontaneous mutant mouse, Asebia (ab), characterized by hypoplastic sebaceous glands and alopecia, was

determined by positional cloning to be a deletion in *Scd1* [36,37]. The conclusion that the *Scd1* gene mutation is responsible for the asebia phenotype was further supported by global *Scd1* gene knockout studies [5]. Whereas global deletion of *Scd1* protected mice against obesity induced by a high carbohydrate diet (HCD), and high-fat diet (HFD), resistance to adiposity was chiefly attributed to increased metabolism. This phenotype was not replicated in tissue-specific KO mice in which *Scd1* is highly expressed, such as in the liver [6], adipose tissue [7], or even in a double KO of *Scd1* in both liver and adipose tissue [8]. Only skin-specific *Scd1* knockout mice increased metabolism to maintain body temperature to compensate for loss of skin-insulating factors [4,9].

A recent report demonstrated that *Scd1* deficiency in adipose tissue-derived mesenchymal stem cells promotes *de novo* beige adipogenesis [19]. The observation that loss of *Scd1* potentiates beige adipocyte formation came from studies on *Scd1*^{ab-Xyk} mice, which exhibit sebaceous gland abnormalities due to *Scd1* function loss [38]. These mice presumably display a hypermetabolic lean phenotype due to the loss of skin-insulating factors, similar to those seen in global *Scd1*KO (GKO) mice [5] and *Scd1*^{ab-2J} mice [36,37]. This effect, including adipose being, was particularly marked when the mice were housed at 22 °C, a temperature below their thermoneutral point [3]. In our study, we did not observe that beige adipocyte markers were induced in *Scd1*KO adipocytes derived from MSCs. This finding was supported in *Scd1*KO adipocytes originating from *Scd1*^{floxex} stromal-vascular cells infected with the *Cre* virus. Divergence in our findings on beige adipocyte formation likely arises from differences in experimental models studied.

3.2. *Scd1*KO adipocytes undergoes ADCD

There are numerous reports linking *Scd1* to cancer cell death [27], yet the specific cell death pathways involved — including apoptosis, ferroptosis, and autophagy — remain controversial. One potential explanation for this diversity of pathways might stem from varying *Scd1* expression in different cells, as well as differential concentrations of *Scd1* inhibitors used in various studies. It is widely recognized that if cells encounter difficulty in triggering their primary programmed cell death pathway, they may alternatively engage a secondary cell death mechanism as a compensatory mechanism [13].

Autophagy is primarily recognized for its cytoprotective role in cellular processes. Compelling evidence suggests that inhibition of essential *Atg* genes can accelerate cell death when the target of selective autophagic degradation comprises pro-death proteins, including caspase 8 [39] and RIPK1 [40]. However, autophagy also has the potential to induce cell death particularly during development and in response to stress, a phenomenon classified as ADCD. To conclusively determine the occurrence of ADCD, three criteria were proposed [13,16]. These include: 1) the exclusion of other forms of cell death, 2) evidence of an increase in autophagic flux, and 3) proof that inhibiting autophagy can rescue the cell from death. Although we weren't able to exclude all 12 major cell death modes [41], we successfully excluded necrosis, apoptosis, and ferroptosis, using TEM and various inhibitors. Despite not detecting increased autophagic flux via immunoblotting, p62 immunocytochemistry revealed that some *Scd1*KO adipocytes were filled with p62 puncta, which further increased with bafilomycin A1 and rapamycin treatment. This observation was supported by the DAPRed (autophagosome) and DALGreen (acidity) stains that revealed the presence of many autolysosomes in *Scd1*KO adipocytes. Another distinct group of adipocytes demonstrated numerous autophagosome puncta that lacked acidification, suggesting potential impairment in the fusion between autophagosomes and lysosomes. This might lead to cell

death, possibly representing a stage of decompensation when a lysosome cannot manage an enhanced autophagosome. This dynamic, consisting of compensational and decompensation phases, resulted in little change in autophagic flux as detected by immunoblotting in *Scd1*KO adipocytes. However, *Atg7* knockout adipocytes were resistant to cell death induced by Scd1 inhibition. Taken together, these findings suggest that inhibition of Scd1 in adipocytes induces ADCD *in vitro*. Morphologically, three types of cell death, including ADCD, are associated with multiple vacuole formations [42]. We excluded paraptosis, characterized by cytoplasmic vacuolation that involves the swelling of the endoplasmic reticulum and mitochondria, as no mitochondrial swelling was observed in *Scd1*KO adipocytes. In addition, methuosis is characterized by electron-lucent cytoplasmic fluid-filled vacuoles resulting from macropinocytosis [43], which also does not fully align with our observations. We observed vacuoles in *Scd1*KO adipocytes by TEM whose contents appeared to have different cargo from controls, or appeared empty, consistent with the characteristics of ADCD due to increased accumulation of autophagosomes positive for p62 positive puncta and lacking acidification.

3.3. Critical roles of lipogenesis for autophagy

Although the exact source of the autophagosomal membrane is still a debated topic, studies suggest that autophagosomes might originate from the ER or from ER-related membranes [15]. MUFAs, which are generated by the ER-associated enzyme Scd1, are key components in the biosynthesis of lipids including phospholipids. Since deletion of Scd1 shifts lipid composition from species containing mono-unsaturated lipids toward species containing saturated lipids in the lipidomic data from whole adipocytes, quantity of MUFAs incorporated into the autophagosome membrane could potentially influence the efficiency and specificity of autophagic processes. Although existing studies provide evidence that lipids are involved in controlling autophagy, they demonstrate a relationship between the composition of phospholipids, the storage of lipid droplets, ER stress, and the biogenesis of autophagosomes [44–46].

There are two recent, intriguing papers related to autophagosome membrane assembly. The yeast Acyl-CoA synthetase, Fatty acid activation protein 1 (Faa1), channels fatty acids into *de novo* phospholipid synthesis and promotes assembly of newly synthesized phospholipids into autophagic membranes [47]. Another paper reported that Fasn colocalizes with nascent autophagosomes [17]. A deficiency of Fasn in adipocytes, both *in vitro* and *in vivo*, markedly impairs autophagy, causing substantial accumulation of autophagosomes [17]. There is no further information regarding the fate of *Fasn*KO adipocytes that have accumulated autophagosomes, including cell death. Interference with cellular transport due to packed autophagosomes, or the disappearance of intact organelles without being sequestered by an autophagosome, are potential mechanisms of ADCD, although the precise mechanisms remain unclear [13,14]. Thus, it is possible that cells with a massive accumulation of autophagosomes in *Fasn*KO adipocytes might also undergo cell death. The results from *Fasn*KO adipocytes uncovered the role of adipocyte DNL in autophagy, as opposed to its relatively minor contribution to adipocyte triacylglycerol storage [17]. Although palmitate was insufficient to restore autophagic flux in *Fasn*KO adipocytes, we speculate that direct supplementation of MUFAs may restore autophagy activity in *Fasn* KO adipocytes. Our experiments indicate that exogenous palmitate is not an efficient substrate for Scd1 in adipocytes, and that supplementation with MUFAs rescues adipocytes from cell death induced by Scd1 depletion. Our studies propose that the MUFAs

produced by Scd1 and potentially incorporated into autophagosome membranes, can influence efficiency and specificity of autophagic processes. Further study is required to define the molecular mechanisms by which MUFAs within the autophagosome membrane regulate autophagy especially in adipocytes.

Several studies address the role of Scd1 or MUFA on autophagosome formation, and autophagosome–lysosome fusion [11,48–51]. Although the observed phenomena are somewhat similar to those highlighted herein, the conclusions drawn are different. For instance, INS-1E pancreatic β -cells treated with 2 μ M A939572, an Scd1 inhibitor, have impairments in autophagic clearance due to defects in autophagosome–lysosome fusion, resulting in apoptosis rather than ADCD, presumably due to ER dysfunction [48]. Human HCC cells treated with 10 μ M CAY10566, another Scd1 inhibitor, induced both apoptosis and autophagy [51]. In contrast, Scd1 inhibitor treatment of mouse embryonic fibroblasts suppressed autophagy at the earliest stage of autophagosome formation [11]. Interestingly, treatment of human osteosarcoma U2OS cells with 500 μ M oleate induced a non-canonical autophagic response, presenting vacuolar structures colocalizing with the Golgi apparatus [50]. Potential explanations for these varied results, diverging from ours, might stem from different levels of Scd1 expression across cell types, varied concentrations of Scd1 inhibitors used, differential toxicity of free fatty acids among cell types evaluated, and differences in underlying metabolism of adipocytes and other cell types.

3.4. Scd1KO does not undergo lysosome-mediated cell death

Lysosome-dependent cell death is defined as a cell death event characterized by massive lysosomal leakage and the ectopic action of lysosomal enzymes [52]. Different forms of stress have been reported to induce lysosomal membrane permeabilization, resulting in lysosomal leakage, which causes an increase in cytosolic acidity and the uncontrolled breakdown of cell components, inducing necrosis [52]. Lysosomal swelling caused by membrane permeabilization is the key morphological feature of this type of cell death. However, we did not observe evidence of lysosome-dependent cell death in our immunocytochemistry with lysosomal markers, staining with dyes for lysosomes, or TEM.

Taken together, our results demonstrate that cool adaptation of adipocytes results in elevated expression of Scd1 in cultured adipocytes and in adipose depots. Our exploration of the functionality of this observation demonstrated that *in vitro* inhibition of Scd1 in adipocytes leads to ADCD, and *in vivo* depletion leads to loss of BMAd. *De novo* synthesis of MUFAs by Scd1 is required for the fusion of autophagosomes to lysosomes, highlighting the essential roles of Scd1 in proper autophagic processes and cell viability. Furthermore, MUFAs play essential roles in maintaining lysosomal and autolysosomal acidification in adipocytes. Lack of *de novo* synthesis of MUFAs by Scd1 results in aberrant accumulation of vacuoles, eventually leading to cell death.

4. METHOD DETAILS

4.1. Animals

Scd1^{fl/fl} mice were provided by Dr. James Ntambi (University of Wisconsin-Madison) and were crossed with BMAd-specific *Cre* mice [25] to generate mice with *Scd1* deficiency in bone marrow adipocytes. All animal studies were performed in compliance with policies of the University of Michigan Institutional Animal Care and Use Committee. The protocol number is PR000009687. All animals were housed in a

12-h light/12-h dark cycle with free access to food and water. Body composition: lean, fat masses were measured by EchoMRI-100H.

4.2. Glucose and insulin tolerance tests

For glucose tolerance tests, mice were fasted for 16 h and then given glucose (1 mg/kg body weight) via intraperitoneal injection. For insulin tolerance tests, mice were fasted for 6 h and then intraperitoneally injected 0.5 U/kg body weight of insulin (Eli Lilly). Glucose concentrations were monitored in blood collected from the tail vein at 0, 15, 30, 60, and 120 min after injection using a glucometer and Contour Next blood glucose strips (Bayer AG).

4.3. Adipocyte and stromal-vascular cell fractionation

Posterior subcutaneous WAT (SWAT) was excised from mice as previously described [3]. WAT depots from *Scd1^{fl/fl}* mice were minced with scissors and digested for 1 h at 37 °C in 2 mg/mL collagenase type I (Worthington Biochemical) in Krebs-Ringer-HEPES (KRH; pH 7.4) buffer containing 3% fatty acid-free bovine serum albumin (BSA; Gold Biotechnology, St. Louis, NJ), 1 g/L glucose, and 500 nM adenosine. The resulting cell suspensions were filtered through 100 µm cell strainers and centrifuged at 100 × *g* for 8 min to pellet stromal-vascular cells (SVC) and float buoyant adipocytes. To induce gene recombination in adipocytes, *Scd1^{fl/fl}* stromal vascular cells were treated with adenoviral GFP or adenoviral Cre recombinase (1 × 10¹⁰ viral particles/mL) in serum-free DMEM:F12 from days 4–6 of differentiation. Adipocytes were then analyzed on day 13 of differentiation. Adenoviruses were obtained from the University of Michigan Vector Core.

4.4. Isolation and differentiation of adipocyte precursors

Mesenchymal precursors were isolated from ears of mice of the indicated genotypes, as previously described [53]. Cells were maintained in 5% CO₂ and DMEM:F12 1:1 media (Gibco; Invitrogen) supplemented with 10% FBS (Cytiva HyClone), primocin (InvivoGen), and 10 ng/mL recombinant bFGF (PeproTech). For induction of adipogenesis, recombinant bFGF was removed and replaced with 10% FBS containing 0.5 mM methylisobutylxanthine, 1 µM dexamethasone, 5 µg/mL insulin, and 5 µM rosiglitazone. On day 2, cells were fed 5 µg/mL insulin plus 5 µM troglitazone. On day 4 and every 2 days thereafter, cells were fed with 10% FBS-supplemented media. All the media conditions used in the experiments within this study contain 10% FBS, unless otherwise specified in the individual figure legends. When using 2% FBS, Insulin-Transferrin-Selenium (ITS) (Gibco; Invitrogen) was supplemented.

4.5. Lysosome enrichment from cultured MSC adipocytes

Lysosomal fraction was enriched using Pierce™ Lysosome Enrichment Kit (Thermo Scientific) according to the manufacturer's instructions. Briefly, both control and *Scd1* KO adipocytes (Day 6 after differentiation; 10 cm dish) were harvested with 2000 µL of Lysosome Enrichment Reagent A, then homogenized by Dounce tissue grinder after vortex on ice. Lysate was mixed with an equal volume of Lysosome Enrichment Reagent B, then centrifuged at 500 × *g* for 10 min at 4 °C to obtain the lysosome-containing supernatant. The buoyant lipid cake was removed after the centrifuge step. After overlaying the supernatant containing 15% OptiPrep Media on top of step-wise density gradients (30%, 27%, 23%, 20% and 17%), samples were ultracentrifuged at 145,000 × *g* for 2 h at 4 °C. Lysosome bands located in the top 2 mL of the gradient after the end of centrifugation were carefully transferred to new tubes, mixed with 3 volumes of PBS to decrease the concentration of the OptiPrep Media, then centrifuged at 18,000 × *g* for 30 min at 4 °C to obtain the lysosome pellet.

4.6. Lipidomics-sample preparation

Tail and tibia samples from *Scd1-KO* and WT mice were pulverized under frozen conditions, transferred into 1.5 mL microcentrifuge tubes, and stored at –80 °C until extraction. For lipidomics of adipocytes, cell plates were rapidly frozen with liquid nitrogen and preserved at –80 °C until extraction. 5 µL of SPLASH (Avanti Polar Lipids) were added to each tube prior to extraction. Chilled extraction solvents were then added to each tube: 85 µL of methanol, 300 µL of methyl tert-butyl ether (MTBE), and 75 µL of water. The samples were sonicated for 5 min using a program of 20 s on, 10 s off, and an amplitude of 30 (Qsonica, chilled bath sonicator), with the temperature maintained at 14 °C. The samples were incubated on ice for 10 min and then centrifuged for 2 min at 14,000 *g* and 4 °C. Subsequently, 100 µL of the upper lipophilic layer was transferred to an amber glass autosampler vial with fused glass insert. This extract was dried using a vacuum. Samples were resuspended in 50 µL of 9:1 methanol:toluene for analysis by LC–MS.

4.7. Lipidomics-LC–MS analysis

Sample analysis was conducted on an Acquity CSH C18 column held at 50 °C (100 mm × 2.1 mm × 1.7 µm particle size; Waters) using a Vanquish Binary Pump (400 µL/min flow rate; Thermo Scientific). Mobile phase A consisted of 10 mM ammonium acetate in ACN:H₂O (70:30, v/v) with 250 µL/L acetic acid. Mobile phase B comprised 10 mM ammonium acetate in IPA:ACN (90:10, v/v) featuring the same additives. The initial condition held mobile phase B at 2% for 2 min. The subsequent gradient was as follows: ramp to 30% over 3 min, increase to 50% over the next 1 min, further rise to 85% over 14 min, and then elevate to 99% over 1 min where %B was maintained at 99% for 7 min. The column was then re-equilibrated with 2% mobile phase B for 1.75 min before the next injection. A 20 µL aliquot of each extract was injected by a Vanquish Split Sampler HT autosampler (Thermo Scientific) in a randomized order. The LC system interfaced with a Q Exactive HF Orbitrap mass spectrometer via a heated electrospray ionization (HESI II) source (Thermo Scientific). Source conditions were as follows: HESI II and capillary temperature at 275 °C, auxiliary gas temperature at 300 °C, sheath gas flow rate at 30 units, auxiliary gas flow rate at 6 units, sweep gas flow rate at 0 units, spray voltage at 1.4.0 kV for both positive and negative modes, and S-lens RF at 60.0 units. The mass spectrometer operated in polarity switching mode to acquire positive and negative full MS and MS₂ spectra (Top2) within the same injection. For both modes, full MS scans were conducted at 30,000 resolution, with 1 × 10⁶ automatic gain control (AGC) target, 100 ms maximum ion accumulation time (max IT), and 200–1600 *m/z* scan range. MS₂ scans adhered to 30,000 resolution, a 1 × 10⁵ AGC target, 50 ms max IT, a 1.0 *m/z* isolation window, stepped normalized collision energy (NCE) at 20, 30, 40, and a 30.0 s dynamic exclusion.

4.8. Lipidomics-data analysis

The resulting LC–MS data were processed using Thermo Scientific software Compound Discoverer 3.1 and LipiDex (PMID: 29705063, v. 1.1.0). Peaks with retention times between 0.4 min and 21 min and MS₁ precursor masses ranging from 100 Da to 5000 Da were compiled into distinct chromatographic profiles (i.e., compound groups) using a 10-ppm mass and a 0.4 min retention time tolerance. Profiles failing to achieve a minimum peak intensity of 1 × 10⁵, a maximum peak width of 0.75, a signal-to-noise (S/N) ratio of 3, and a 5-fold intensity increase over blanks were excluded from further processing. MS/MS spectra were matched against an in-silico-generated lipid spectral library containing 35,000 unique molecular compositions representing 48 distinct lipid classes. Spectral matches achieving a dot product score greater than 500 and a reverse dot

product score greater than 700 were considered for further analysis. Lipid MS/MS spectra showing minimal interference (<75%) from coeluting isobaric lipids, eluting within a 3.5 median absolute retention time deviation (M.A.D. RT) of each other, and observed in at least 3 processed files were identified at the individual fatty acid substituent level of structural resolution. Identifications were made by summing the fatty acid substituents if individual fatty acid substituents remained unresolved.

4.9. Detection of specific proteins by immunoblot

After lysis in 1% NP-40, 120 mM NaCl, 50 mM Tris-HCl (pH 7.4), 50 mM NaF, 2 mM EDTA, 1× protease inhibitor cocktail (Sigma-Aldrich), protein concentrations of lysates after centrifugation were measured by BCA protein assay (Thermo Fisher Scientific). Lysates were diluted to equal protein concentrations in lysis buffer and then boiled in SDS sample buffer (20 mM Tris; pH 6.8, 2% SDS, 0.01% bromophenol blue, 10% glycerol, 5% 2-mercaptoethanol) and subjected to SDS-PAGE and immunoblotting according to standard techniques [3].

4.10. Immunocytochemistry (ICC)

MSCs were seeded on sterile 12 mm #1.5 round coverslips in 12 well plates, then differentiated into adipocytes. Adipocytes with coverslips were incubated with 4% paraformaldehyde for fixation, with 0.5% Triton X-100 in TBS for permeabilization. Adipocytes were then incubated with primary antibodies solution in 2% BSA for 1 h at room temperature (RT) after blocking with 2% BSA, then incubated with fluorescent-dye conjugated secondary antibodies in 2% BSA for 1 h at RT. The coverslip was placed onto a glass slide with ProLong Gold Antifade (ThermoFisher) after counter-staining with Hoechst 33342 (Cayman Chemical; 5 µg/mL).

4.11. Cell imaging with fluorescent dye, and time-lapse image

The LIVE/DEAD Viability/Cytotoxicity Kit (Invitrogen: L3224) was used following the manufacturer's instructions to evaluate cell survival. Cells were stained with 2 µM calcein-AM (green) and 4 µM ethidium homodimer I (red) for 30 min. To assess dead cells, adipocytes were incubated with 0.2 % Trypan Blue Solution (Fisher Scientific) in Phosphate Buffered Saline for 3 min, then washed with DMEM/F12 media for taking photos. Hoechst 33342 was used for staining nuclei of either living or fixed cells. Time-lapse imaging was performed using a Cytation 5 automated imager with BioSpa-System (BioTek; University of Michigan Frankel Cardiovascular Regeneration Core Laboratory).

4.12. Histology

Tibiae were first fixed by formalin, then decalcified with 14% EDTA for at least two weeks, followed by additional fixation in 4% paraformaldehyde. Soft tissues were fixed with formalin, and both tibiae and soft tissues were embedded in paraffin blocks, which were sectioned and stained with hematoxylin and eosin. Stained tibiae and soft tissues were then imaged on an Olympus BX51 microscope. Adipocyte cross-sectional areas were measured using MetaMorph software.

4.13. Osmium tetroxide staining and µCT analysis of bone marrow lipid

Specimens placed in a 19 mm diameter specimen holder and scanned using a microCT system (µCT100 Scanco Medical, Bassersdorf, Switzerland). Scan settings were: voxel size 12 µm, 70 kVp, 114 µA, 0.5 mm AL filter, and integration time 500 ms. Analysis was performed using the manufacturer's evaluation software, and a fixed global threshold of 28% (280 on a grayscale of 0–1000) for cortical bone and 25.5% (255 on a grayscale of 0–1000) for trabecular bone was used to segment bone from non-bone. A 1 mm region of trabecular bone was analyzed immediately below the growth plate and a 1.5 mm region around the midpoint of the tibia and a region from the tibia-fibula junction to the distal end.

After the analysis of bone variables, mouse tibiae were decalcified for staining with osmium tetroxide, using a method previously published [25]. Additionally, a lower threshold (300 gray-scale units) was employed for the quantification of proximal tibial rBMAT because the density of osmium staining is lower due to the smaller adipocyte size. A threshold of 400 gray-scale units was used for cBMAT in the distal tibia.

4.14. Statistics

All data are presented as mean ± SD. When comparing 2 groups, significance was determined using 2-tailed Student t test. When comparing multiple experimental groups, an analysis of variance (ANOVA) was followed by post hoc analyses with Dunnett or Sidak test, as appropriate. Differences were considered significant at $p < 0.05$ and are indicated with asterisks. For metabolomics data analyses, the proportion of labeling at each carbon position was calculated by dividing each species by total sum of peak areas of all labeled positions. The proportion of data is well known to follow a beta distribution. Beta regression model is an extension of the generalized linear model with an assumption that the response variable follows a beta distribution with values in standard unit interval (0,1).

Mouse and primary cells	Source	Order number
<i>Scd1^{fl/fl}</i> mice	Dr. James Ntambi (University of Wisconsin—Madison, USA)	
BMA-specific Cre mice	MacDougald lab [25]	
<i>Scd1</i> KO and control MSCs isolated from <i>Scd1</i> KO and control mice, respectively.	Dr. James Ntambi (University of Wisconsin—Madison, USA)	
MSCs isolated from <i>Atg7^{fl/fl}</i> mice.	Dr. Rajat Singh (University of California, Los Angeles, USA)	
Chemicals, peptides, and recombinant proteins		
A-939572	Cayman Chemical	19123
bafilomycin A1	Cayman Chemical	11038
CAY10566	Cayman Chemical	10012562
Ferrostatin-1	Cayman Chemical	17729
GSK872	Cayman Chemical	23300
Liproxstatin	Cayman Chemical	17730
MF-438	Millipore Sigma	569406

— (continued)

Necrostatin-2	Cayman Chemical	20924
Necrosulfonamide	Cayman Chemical	20844
Rapamycin	Cayman Chemical	13346
SM164	Cayman Chemical	28632
SRS11-92	Cayman Chemical	25689
Recombinant Murine TNF- α	PeprTech	315-01A
Thapsigargin	Cayman Chemical	10522
Tunicamycin	Cayman Chemical	11445
Z-VAD(OMe)-FMK	Cayman Chemical	14463
Fatty acid		
Oleic acid	Sigma-Aldrich	
Palmitoleic acid	Sigma-Aldrich	
Sodium palmitate	Sigma-Aldrich	
Fatty acid-free bovine serum albumin	Gold Biotechnology	
Kit		
Lysosome Enrichment Kit Pierce™	Thermo Scientific,	89839
Fluorescent dye, others for staining		
BODIPY™ 493/503	Thermo Fisher Scientific	D392
LIVE/DEAD viability/cytotoxicity kit	Invitrogen	L3224
Trypan Blue Solution	Thermo Fisher Scientific	
Hoechst 33342	Cayman Chemical	
ProLong Gold Antifade	Thermo Fisher Scientific	
LysoPrime Green	Dojindo	L261-12
pHLys Red	Dojindo	L265-12
DAPRed	Dojindo	D677-10
DALGreen	Dojindo	D675-10
Culture media		
DMEM, low glucose, GlutaMAX™	Thermo Fisher Scientific	10567014
Antibodies		
Adiponectin	Sigma Aldrich	A6354
AMPK α (23A3)	Cell Signaling Technology	#2603S
ABHD6 (D3C8N)	Cell Signaling Technology	#97573
ATP6V0A1	Novus Biologicals	NBP1-89342
Cleaved Caspase 3 (Asp175)	Cell Signaling Technology	#9664
Caspase-3 (D3R6Y)	Cell Signaling Technology	#14220
ERK 2	Santa Cruz Biotechnology	sc-1647
FASN	Abcam	ab22759
FABP4	R&D	#1443
Laminin	Novus Biologicals	NB300-144
LAMP1/CD107a	Novus Biological	AF4320
LAMP2 [GL2A7]	Abcam	ab13524
LC3B (D11)	Cell Signaling Technology	#3868
LIMP2/SCARB2	Cell Signaling Technology	#27960
P-MLKL (Ser345)	Cell Signaling Technology	#37333S
MLKL antibody	Proteintech	6667566675
Perilipin	Abcam	ab61682
Sqstm1/p62 Rodent specific	Cell Signaling Technology	#23214
S6RP	Cell Signaling	2211
p-S6RP	Cell Signaling	4857
SCD1	Cell Signaling	2438
UCP1	Alpha Diagnostic	UCP11-A
Donkey anti-Rat IgG (H + L) Alexa Fluor 568	Thermo Fisher Scientific	#A-78946
Donkey anti-Rabbit IgG (H + L) Alexa Fluor 647	Thermo Fisher Scientific	#A-31573
Donkey anti-goat IgG (H + L) Alexa Fluor 488	Thermo Fisher Scientific	#A-11055

qPCR primers used were as follows;

Gene name	Forward	Reverse
Cox8b	GAACCATGAAGCCAACGACT	GCGAAGTTCACAGTGGTTCC
Fgf21	CAAACTCTGGGTGTCAAAGC	CATGGGCTTCAGACTGGTAC
Gapdh	TGACGTGCCCGCTGGAGAAA	AGTGTAGCCCAAGATGCCCTTCAG
Hprt	TCATTATGCCGAGGATTTGGA	GCACACAGAGGGCCACAAT
Ppargc1a	AAGTGTGGAACCTCTGGAACCTG	GGGTTATCTTGGTTGGCTTTATG
Ppia	CACCGTGTCTTCGACATCA	CAGTGCTCAGAGCTCGAACT
Prdm16	CCACCAGCGAGGACTTAC	GGAGGACTCTCGTAGCTCGAA
Rpl32	GAGCAACAAGAAAACCAAGCA	TGCACACAAGCCATCTACTCA
Ucp1	GGCCCTTGTAACAACAAAATAC	GGCAACAAGAGCTGACAGTAAAT

CREDIT AUTHORSHIP CONTRIBUTION STATEMENT

Hiroyuki Mori: Writing — original draft, Investigation, Formal analysis, Data curation, Conceptualization. **Sydney K. Peterson:** Investigation, Formal analysis, Data curation. **Rachel C. Simmermon:** Investigation, Formal analysis, Data curation. **Katherine A. Overmyer:** Methodology, Investigation. **Akira Nishii:** Visualization, Formal analysis, Data curation. **Emma Paulsson:** Investigation, Formal analysis, Data curation. **Ziru Li:** Data curation. **Annie Jen:** Data curation. **Romina M. Uranga:** Data curation. **Jessica N. Maung:** Data curation. **Warren T. Yacawych:** Data curation. **Kenneth T. Lewis:** Data curation. **Rebecca L. Schill:** Data curation. **Taryn Hetrick:** Data curation. **Ryo Seino:**

Supervision. **Ken Inoki:** Supervision, Funding acquisition. **Joshua J. Coon:** Supervision, Funding acquisition. **Ormond A. MacDougald:** Writing — review & editing, Supervision, Funding acquisition, Conceptualization.

ACKNOWLEDGMENTS

This work was supported by grants or fellowships from the NIH to OAM (R01 DK121759; R01 DK125513, and R01 DK130879), ZL (1P20GM121301), JM (F31 DK135181), KTL (T32 DK071212; F32 DK122654), RLS (T32 DK101357; F32 DK123887), KI (R01DK124709; R01GM145631), and JC (P41 GM108538). ZL was supported by a fellowship from the American Diabetes Association (1-18-PDF-087). This research was also supported by core facilities of the Michigan Integrative Musculoskeletal Health Core Center (P30 AR069620), Michigan Diabetes Research Center (P30 DK020572), Michigan Nutrition and Obesity Center (P30 DK089503), and University of Michigan Frankel Cardiovascular Regeneration Core Laboratory, Histology core (National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under P30 AR069620), SoD mCT Core (NIH/NCRR S10RR026475-01). We thank Hannah Thompson, Maria Del Mar Mendez Casillas, and Lanna Lewis for technical assistance and members of the MacDougald lab for helpful discussions and assistance.

DECLARATION OF COMPETING INTEREST

JC is a consultant for Thermo Fisher Scientific, Seer, and 908 Devices.

DATA AVAILABILITY

Data will be made available on request.

APPENDIX A. SUPPLEMENTARY DATA

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.molmet.2024.101916>.

REFERENCES

- [1] Webb P. Temperatures of skin, subcutaneous tissue, muscle and core in resting men in cold, comfortable and hot conditions. *Eur J Appl Physiol Occup Physiol* 1992;64:471–6.
- [2] Bazett HC, McGlone B. Temperature gradients in the tissues in man. *Am J Physiol* 1927;82:415–51.
- [3] Mori H, Dugan CE, Nishii A, Benchamana A, Li Z, Cadenhead TST, et al. The molecular and metabolic program by which white adipocytes adapt to cool physiologic temperatures. *PLoS Biol* 2021;19:e3000988.
- [4] ALJohani AM, Syed DN, Ntambi JM. Insights into stearoyl-CoA desaturase-1 regulation of systemic metabolism. *Trends Endocrinol Metab* 2017;28:831–42.
- [5] Miyazaki M, Man WC, Ntambi JM. Targeted disruption of stearoyl-CoA desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid. *J Nutr* 2001;131:2260–8.
- [6] Miyazaki M, Flowers MT, Sampath H, Chu K, Otzelberger C, Liu X, et al. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. *Cell Metab* 2007;6:484–96.
- [7] Hyun CK, Kim ED, Flowers MT, Liu X, Kim E, Strable M, et al. Adipose-specific deletion of stearoyl-CoA desaturase 1 up-regulates the glucose transporter GLUT1 in adipose tissue. *Biochem Biophys Res Commun* 2010;399:480–6.
- [8] Flowers MT, Ade L, Strable MS, Ntambi JM. Combined deletion of SCD1 from adipose tissue and liver does not protect mice from obesity. *J Lipid Res* 2012;53:1646–53.
- [9] Sampath H, Flowers MT, Liu X, Paton CM, Sullivan R, Chu K, et al. Skin-specific deletion of stearoyl-CoA desaturase-1 alters skin lipid composition and protects mice from high fat diet-induced obesity. *J Biol Chem* 2009;284:19961–73.
- [10] Ogasawara Y, Kira S, Mukai Y, Noda T, Yamamoto A. Ole1, fatty acid desaturase, is required for Atg9 delivery and isolation membrane expansion during autophagy in *Saccharomyces cerevisiae*. *Biol Open* 2017;6:35–40.
- [11] Ogasawara Y, Itakura E, Kono N, Mizushima N, Arai H, Nara A, et al. Stearoyl-CoA desaturase 1 activity is required for autophagosome formation. *J Biol Chem* 2014;289:23938–50.
- [12] Tan SH, Shui G, Zhou J, Shi Y, Huang J, Xia D, et al. Critical role of SCD1 in autophagy regulation via lipogenesis and lipid rafts-coupled AKT-FOXO1 signaling pathway. *Autophagy* 2014;10:226–42.
- [13] Schwartz LM. Autophagic cell death during development — ancient and mysterious. *Front Cell Dev Biol* 2021;9:656370.
- [14] Ikeda S, Zablocki D, Sadoshima J. The role of autophagy in death of cardiomyocytes. *J Mol Cell Cardiol* 2022;165:1–8.
- [15] Yang Y, Zheng L, Zheng X, Ge L. Autophagosomal membrane origin and formation. *Adv Exp Med Biol* 2021;1208:17–42.
- [16] Shen HM, Codogno P. Autophagic cell death: Loch Ness monster or endangered species? *Autophagy* 2011;7:457–65.
- [17] Rowland LA, Guilherme A, Henriques F, DiMarzio C, Munroe S, Wetoska N, et al. De novo lipogenesis fuels adipocyte autophagosome and lysosome membrane dynamics. *Nat Commun* 2023;14:1362.
- [18] Gross AS, Zimmermann A, Pendl T, Schroeder S, Schoenlechner H, Knittelfelder O, et al. Acetyl-CoA carboxylase 1-dependent lipogenesis promotes autophagy downstream of AMPK. *J Biol Chem* 2019;294:12020–39.
- [19] Liu K, Lin L, Li Q, Xue Y, Zheng F, Wang G, et al. Scd1 controls de novo beige fat biogenesis through succinate-dependent regulation of mitochondrial complex II. *Proc Natl Acad Sci U S A* 2020;117:2462–72.
- [20] Xue H, Wang Z, Hua Y, Ke S, Wang Y, Zhang J, et al. Molecular signatures and functional analysis of beige adipocytes induced from in vivo intra-abdominal adipocytes. *Sci Adv* 2018;4:eaar5319.
- [21] Wu J, Bostrom P, Sparks LM, Ye L, Choi JH, Giang AH, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. *Cell* 2012;150:366–76.
- [22] Garcia RA, Roemmich JN, Claycombe KJ. Evaluation of markers of beige adipocytes in white adipose tissue of the mouse. *Nutr Metab* 2016;13:24.
- [23] Pilkington AC, Paz HA, Wankhade UD. Beige adipose tissue identification and marker specificity-overview. *Front Endocrinol* 2021;12:599134.
- [24] Zou Y, Wang YN, Ma H, He ZH, Tang Y, Guo L, et al. SCD1 promotes lipid mobilization in subcutaneous white adipose tissue. *J Lipid Res* 2020;61:1589–604.
- [25] Li Z, Bowers E, Zhu J, Yu H, Hardij J, Bagchi DP, et al. Lipolysis of bone marrow adipocytes is required to fuel bone and the marrow niche during energy deficits. *Elife* 2022;11.
- [26] Li Z, Bagchi DP, Zhu J, Bowers E, Yu H, Hardij J, et al. Constitutive bone marrow adipocytes suppress local bone formation. *JCI Insight* 2022;7.
- [27] Sen U, Coleman C, Sen T. Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis. *Trends Cancer* 2023;9:480–9.
- [28] Roongta UV, Pabalan JG, Wang X, Ryseck RP, Fargnoli J, Henley BJ, et al. Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy. *Mol Cancer Res* 2011;9:1551–61.

- [29] Peck B, Schug ZT, Zhang Q, Dankworth B, Jones DT, Smethurst E, et al. Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. *Cancer Metab* 2016;4:6.
- [30] Chen L, Ren J, Yang L, Li Y, Fu J, Li Y, et al. Stearoyl-CoA desaturase-1 mediated cell apoptosis in colorectal cancer by promoting ceramide synthesis. *Sci Rep* 2016;6:19665.
- [31] Noto A, Raffa S, De Vitis C, Roscilli G, Malpicci D, Coluccia P, et al. Stearoyl-CoA desaturase-1 is a key factor for lung cancer-initiating cells. *Cell Death Dis* 2013;4:e947.
- [32] Tesfay L, Paul BT, Konstorum A, Deng Z, Cox AO, Lee J, et al. Stearoyl-CoA desaturase 1 protects ovarian cancer cells from ferroptotic cell death. *Cancer Res* 2019;79:5355–66.
- [33] Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)(1). *Autophagy* 2021;17:1–382.
- [34] Wong YC, Kim S, Peng W, Krainc D. Regulation and function of mitochondria-lysosome membrane contact sites in cellular homeostasis. *Trends Cell Biol* 2019;29:500–13.
- [35] Zhang J, Zeng W, Han Y, Lee WR, Liou J, Jiang Y. Lysosomal LAMP proteins regulate lysosomal pH by direct inhibition of the TMEM175 channel. *Mol Cell* 2023;83:2524–2539 e2527.
- [36] Sweet HO, Lane PW. Asebia-J on chromosome 19. *Mouse News Lett* 1977;57.
- [37] Sundberg JP, Boggess D, Sundberg BA, Eilertsen K, Parimoo S, Filippi M, et al. Asebia-2J (Scd1(ab2J)): a new allele and a model for scarring alopecia. *Am J Pathol* 2000;156:2067–75.
- [38] Lu Y, Bu L, Zhou S, Jin M, Sundberg JP, Jiang H, et al. Scd1ab-Xyk: a new asebia allele characterized by a CCC trinucleotide insertion in exon 5 of the stearyl-CoA desaturase 1 gene in mouse. *Mol Genet Genom* 2004;272:129–37.
- [39] Hou W, Han J, Lu C, Goldstein LA, Rabinowich H. Autophagic degradation of active caspase-8: a crosstalk mechanism between autophagy and apoptosis. *Autophagy* 2010;6:891–900.
- [40] Lim J, Park H, Heisler J, Maculins T, Roose-Girma M, Xu M, et al. Autophagy regulates inflammatory programmed cell death via turnover of RHIM-domain proteins. *Elife* 2019;8.
- [41] Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. *Cell Death Differ* 2018;25:486–541.
- [42] Ritter M, Bresgen N, Kerschbaum HH. From pinocytosis to methuosis-fluid consumption as a risk factor for cell death. *Front Cell Dev Biol* 2021;9:651982.
- [43] Shubin AV, Demidyuk IV, Komissarov AA, Rafieva LM, Kostrov SV. Cytoplasmic vacuolization in cell death and survival. *Oncotarget* 2016;7:55863–89.
- [44] Fu S, Yang L, Li P, Hofmann O, Dicker L, Hide W, et al. Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. *Nature* 2011;473:528–31.
- [45] Yang L, Li P, Fu S, Calay ES, Hotamisligil GS. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. *Cell Metab* 2010;11:467–78.
- [46] Velazquez AP, Tatsuta T, Ghillebert R, Drescher I, Graef M. Lipid droplet-mediated ER homeostasis regulates autophagy and cell survival during starvation. *J Cell Biol* 2016;212:621–31.
- [47] Schutter M, Giavalisco P, Brodessaer S, Graef M. Local fatty acid channeling into phospholipid synthesis drives phagophore expansion during autophagy. *Cell* 2020;180:135–149 e114.
- [48] Janikiewicz J, Hanzelka K, Dziewulska A, Kozinski K, Dobrzyn P, Bernas T, et al. Inhibition of SCD1 impairs palmitate-derived autophagy at the step of autophagosome-lysosome fusion in pancreatic beta-cells. *J Lipid Res* 2015;56:1901–11.
- [49] Kohler K, Brunner E, Guan XL, Boucke K, Greber UF, Mohanty S, et al. A combined proteomic and genetic analysis identifies a role for the lipid desaturase Desat1 in starvation-induced autophagy in Drosophila. *Autophagy* 2009;5:980–90.
- [50] Niso-Santano M, Malik SA, Pietrocola F, Bravo-San Pedro JM, Marino G, Cianfanelli V, et al. Unsaturated fatty acids induce non-canonical autophagy. *EMBO J* 2015;34:1025–41.
- [51] Huang GM, Jiang QH, Cai C, Qu M, Shen W. SCD1 negatively regulates autophagy-induced cell death in human hepatocellular carcinoma through inactivation of the AMPK signaling pathway. *Cancer Lett* 2015;358:180–90.
- [52] Wang F, Gomez-Sintes R, Boya P. Lysosomal membrane permeabilization and cell death. *Traffic* 2018;19:918–31.
- [53] Mori H, Prestwich TC, Reid MA, Longo KA, Gerin I, Cawthorn WP, et al. Secreted frizzled-related protein 5 suppresses adipocyte mitochondrial metabolism through WNT inhibition. *J Clin Investig* 2012;122:2405–16.